Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy

Support Care Cancer. 2016 Apr;24(4):1789-93. doi: 10.1007/s00520-015-2978-0. Epub 2015 Oct 7.

Abstract

Purpose: The purpose of this study is to compare the incidence and severity of nephrotoxicity in patients receiving cisplatin with saline hydration vs. saline hydration with mannitol.

Methods: Retrospective chart review of all patients receiving a starting dose of cisplatin 100 mg/m(2) with concurrent radiation for SCCHN between January 1, 2009 and March 1, 2013. All patients received pre and post hydration each with 1 l of 0.9 % saline. The mannitol group received 12.5 g of mannitol in the prehydration fluid. The primary outcome was to compare the rate of grade 3 or greater serum creatinine (SCr) increase in patients receiving saline hydration vs. the addition of mannitol; additional parameters of interest included creatinine clearance, electrolyte disturbances, dose changes, and discontinuation of cisplatin.

Results: Data from 139 patients (80 % male) with a median age of 56 years (range 22 to 75 years) were collected; 88 received mannitol and 51 received saline alone. On multivariable analysis, the mannitol group was less likely to have grade 3 SCr increase than saline only group (OR 0.16; 95 % CI 0.04-0.65; p value = 0.01). There were no grade 4 SCr increase events. Rates of hypomagnesemia and hypokalemia were similar across groups. Grade 3 hyponatremia was more likely to occur in the mannitol group as compared to saline alone group (41 vs 22 %; p = 0.026).

Conclusion: The addition of mannitol to saline hydration decreased the incidence of grade 3 increases in SCr in this cohort of patients and may increase rates of hyponatremia. Further investigations of methods to lessen cisplatin-induced nephrotoxicity are needed.

Keywords: Cisplatin; Hydration; Mannitol; Nephrotoxicity; Prevention.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / adverse effects*
  • Chemoradiotherapy / adverse effects
  • Cisplatin / adverse effects*
  • Diuretics, Osmotic / administration & dosage*
  • Female
  • Head and Neck Neoplasms / therapy*
  • Humans
  • Hypokalemia / chemically induced
  • Kidney Diseases / chemically induced
  • Kidney Diseases / prevention & control*
  • Magnesium Deficiency / chemically induced
  • Male
  • Mannitol / administration & dosage*
  • Middle Aged
  • Neoplasms, Squamous Cell / drug therapy*
  • Retrospective Studies
  • Sodium Chloride / administration & dosage

Substances

  • Antineoplastic Agents
  • Diuretics, Osmotic
  • Mannitol
  • Sodium Chloride
  • Cisplatin